A graduate of Harvard College, Dr. Segal completed a combined residency in internal medicine and pediatrics, as well as a fellowship in rheumatology, at Massachusetts General Hospital, achieving certification in all three specialties. Following postdoctoral training at the prestigious Whitehead Institute, he founded and served as CEO of a biotechnology company that developed immunotherapies for cancer, chronic infectious diseases, and other disorders. In addition to serving as CEO, Dr. Segal obtained and was Principal Investigator on 7 NIH grants.